FTC Sues Daraprim Maker; Alleges ‘Elaborate Anticompetitive Scheme’

The Federal Trade Commission is suing Vyera Pharmaceuticals and former CEO Martin Shkreli for allegedly creating an elaborate anticompetitive scheme to preserve a monopoly on Daraprim after jacking up the price of the parasitic infection drug by 4,000%. The FTC complaint alleges Shkreli was directly responsible for orchestrating the anticompetitive scheme, as well as Phoenixus AG, Vyera’s parent company. FTC and the New York State Office of the Attorney General jointly filed the lawsuit against Vyera, which was named Turing...